Clearance of senescent cells with ABT-263 improves biological functions of synovial mesenchymal stem cells from osteoarthritis patients

Yugo Miura,Kentaro Endo,Keiichiro Komori,Ichiro Sekiya
DOI: https://doi.org/10.1186/s13287-022-02901-4
2022-06-04
Abstract:Osteoarthritis (OA) is an age-related joint disease characterized by progressive cartilage loss. Synovial mesenchymal stem cells (MSCs) are anticipated as a cell source for OA treatment; however, synovial MSC preparations isolated from OA patients contain many senescent cells that inhibit cartilage regeneration through their senescence-associated secretory phenotype (SASP) and poor chondrogenic capacity. The aim of this study was to improve the biological function of OA synovial MSCs by removing senescent cells using the senolytic drug ABT-263.
cell biology,medicine, research & experimental,cell & tissue engineering
What problem does this paper attempt to address?